ALBUQUERQUE, N.M., Oct. 27 The Board of Directors of Biomoda, Inc. (OTC Bulletin Board: BMOD), (www.biomoda.com) an early cancer detection medical diagnostics company, has elected Maria Zannes to serve as Corporate Secretary. Zannes originally joined the Biomoda Board May 1, 2008.
Advertisement
"Maria's extraordinary background in corporate and legal affairs makes her the perfect individual to safeguard our commitment to good corporate governance," said John Cousins, Biomoda president and chief executive officer. "As we progress through clinical trials with the Biomoda diagnostic, Maria's expertise will keep us focused on best practices and regulatory compliance."
Advertisement
Zannes replaces Verrity Gershin in the post. "The board wants to acknowledge Verrity's commitment to Biomoda and her work with the company over the years. We're pleased that she will continue to serve as office manager and provide the critical support necessary to get our lifesaving technology to the marketplace," Cousins said.
Zannes brings more than 30 years of experience in the environmental and energy industries where she worked in multiple capacities, including federal lobbyist and company president. Formerly president of a national waste-to-energy trade group in Washington, D.C., Zannes currently consults for private clients in the medical, energy, and environmental industries. She is a research associate for Columbia University's Earth Engineering Center and a member of the Board of Directors of American Homecoming Foundation, a non-profit organization focused on providing assistance to homeless veterans. She was a legislative aide and press secretary to U.S. Rep. Charles Wilson (D-Texas). Zannes is licensed to practice law in Washington State and New Mexico.
Biomoda's first product, an in-vitro test for the early detection of lung cancer trademarked as CyPath®, is based on a patented porphyrin-based compound that binds to cancer cells and fluoresces red under ultraviolet light. Originally developed at Los Alamos National Laboratory, the molecular marker technology is the foundation for several Biomoda product lines and medical tools still in the developmental stage.
SOURCE Biomoda, Inc.
